The anti-tumour activity of pemigatinib, a selective inhibitor of FGFR 1–3, was evaluated in the phase 2 study FIGHT-202 (NCT02924376) in 146 patients with previously treated metastatic CCA, with and without FGFR2 alterations. Here, FGFR2 is linked to neoplasm.